These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30728222)

  • 1. Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome.
    Gerbaud E; Darier R; Montaudon M; Beauvieux MC; Coffin-Boutreux C; Coste P; Douard H; Ouattara A; Catargi B
    Diabetes Care; 2019 Apr; 42(4):674-681. PubMed ID: 30728222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Calprotectin Levels and Outcome Following Percutaneous Coronary Intervention in Patients with Diabetes and Acute Coronary Syndrome.
    Wang C; Kong Y; Ding Y; Sun J; Chen T
    Med Sci Monit; 2019 Dec; 25():9517-9523. PubMed ID: 31834876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic Variability and Hyperglycaemia as Prognostic Markers of Major Cardiovascular Events in Diabetic Patients Hospitalised in Cardiology Intensive Care Unit for Acute Heart Failure.
    Gerbaud E; Bouchard de La Poterie A; Baudinet T; Montaudon M; Beauvieux MC; Lemaître AI; Cetran L; Seguy B; Picard F; Vélayoudom FL; Ouattara A; Kabore R; Coste P; Domingues-Dos-Santos P; Catargi B
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved predictive value of GRACE risk score combined with platelet reactivity for 1-year cardiovascular risk in patients with acute coronary syndrome who underwent coronary stent implantation.
    Li S; Liu H; Liu J; Wang H
    Platelets; 2016 Nov; 27(7):650-657. PubMed ID: 27809713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention.
    Bai XF; Zhang YP; Zhou J; Wu Y; Li RF; Sun LZ; Ma QQ; Lou BW; Zhai BW; Liu MP; Cheng LL; Tong XN; Yuan ZY
    Thromb Res; 2018 Oct; 170():142-147. PubMed ID: 30193195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of in-hospital glycemic variability and admission blood glucose in predicting short-term outcomes in non-diabetes patients with ST elevation myocardial infarction underwent percutaneous coronary intervention.
    Mi SH; Su G; Yang HX; Zhou Y; Tian L; Zhang T; Tao H
    Diabetol Metab Syndr; 2017; 9():20. PubMed ID: 28344659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glycemic variability on short term prognosis in acute myocardial infarction subjects undergoing primary percutaneous coronary interventions.
    Zhang JW; He LJ; Cao SJ; Yang Q; Yang SW; Zhou YJ
    Diabetol Metab Syndr; 2014; 6():76. PubMed ID: 25013458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical and angiographic prognostic risk scores in elderly patients presenting with acute coronary syndrome and referred for percutaneous coronary intervention.
    Vassalli G; d'Angeli I; Scherff F; Sürder D; Mantovani A; Pasotti E; Klersy C; Auricchio A; Moccetti T; Pedrazzini GB
    Swiss Med Wkly; 2015; 145():w14049. PubMed ID: 25658654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of the CHA
    Peng H; Sun Z; Chen H; Zhang Y; Ding X; Zhao XQ; Li H
    Am J Cardiol; 2019 Aug; 124(4):476-484. PubMed ID: 31235063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of pulse wave velocity with clinical factors as a promising tool to predict major adverse cardiac events after percutaneous coronary intervention.
    Chen BW; Wang ZG; Liu Q; Wang X; Dang A
    J Cardiol; 2015 Apr; 65(4):318-23. PubMed ID: 25048178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and outcomes of patients with suspected acute coronary syndromes in relation to initial diagnostic impressions (insights from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]).
    Bajaj RR; Goodman SG; Yan RT; Bagnall AJ; Gyenes G; Welsh RC; Eagle KA; Brieger D; Ramanathan K; Grondin FR; Yan AT;
    Am J Cardiol; 2013 Jan; 111(2):202-7. PubMed ID: 23122889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated with 30-day Major Adverse Cardiovascular Event in Acute Coronary Syndrome Patients with Non-Dialysis Chronic Kidney Disease: A Retrospective Cohort Study.
    Ginanjar E; Hustrini NM; Mansjoer A; Al Hanif MS
    Acta Med Indones; 2023 Jan; 55(1):10-18. PubMed ID: 36999254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The burden of major adverse cardiac events in patients with coronary artery disease.
    Tsai IT; Wang CP; Lu YC; Hung WC; Wu CC; Lu LF; Chung FM; Hsu CC; Lee YJ; Yu TH
    BMC Cardiovasc Disord; 2017 Jan; 17(1):1. PubMed ID: 28052754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of myeloperoxidase concentration in patients with acute coronary syndrome].
    Liu SC; Yi TC; Weng HY; Zhang L; Li YX; Mohetaboer M; Zhang Y; Jiang J; Li JP; Huo Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Apr; 46(4):284-291. PubMed ID: 29747324
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive value of the stress hyperglycemia ratio in dialysis patients with acute coronary syndrome: insights from a multi-center observational study.
    Xie E; Ye Z; Wu Y; Zhao X; Li Y; Shen N; Gao Y; Zheng J
    Cardiovasc Diabetol; 2023 Oct; 22(1):288. PubMed ID: 37891639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum gamma-glutamyl transferase activity: new high-risk criteria in acute coronary syndrome patients?
    Ulus T; Yildirir A; Sade LE; Temiz A; Polat E; Bozbaş H; Aydinalp A; Eroğlu S; Ozin B; Müderrisoğlu H
    Coron Artery Dis; 2008 Nov; 19(7):489-95. PubMed ID: 18923245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of blood adipose tissue hormones concentration--adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction.
    Piestrzeniewicz K; Luczak K; Goch JH
    Neuro Endocrinol Lett; 2008 Aug; 29(4):581-8. PubMed ID: 18766137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the index of microcirculatory resistance after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
    Murai T; Yonetsu T; Kanaji Y; Usui E; Hoshino M; Hada M; Hamaya R; Kanno Y; Lee T; Kakuta T
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):1063-1074. PubMed ID: 29446567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for non-ST-elevation acute coronary syndromes.
    Elbarouni B; Ismaeil N; Yan RT; Fox KA; Connelly KA; Baer C; DeYoung JP; Gallo R; Ramanathan K; Pesant Y; Leiter LA; Goodman SG; Yan AT
    Am Heart J; 2011 Aug; 162(2):347-355.e1. PubMed ID: 21835297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications and pharmacological considerations of glycemic variability in patients with type 2 diabetes mellitus.
    Howsawi AA; Alem MM
    Sci Rep; 2024 Oct; 14(1):24062. PubMed ID: 39402124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.